Table 2.
Treatment adherence to GOLD 2010
| GOLD stage | Appropriate treatment | n (%) | Inappropriate treatment | n (%) |
|---|---|---|---|---|
| I | Short-acting | 1 (6.25) | LAMA | 6 (37.5) |
| bronchodilators when | 1 (6.25) | LAMA-LABA | 1 (6.25) | |
| needed | LABA-ICS | 1 (6.25) | ||
| Total | LAMA-T | 1 (6.25) | ||
| LABA-ICS-LAMA | 6 (37.5) | |||
| Total | 15 (93.75) | |||
| II | LAMA | 12 (5) | ICS | 8 (3.4) |
| LABA-LAMA | 20 (8.4) | LABA-ICS | 30 (12.6) | |
| LAMA-T | 3 (1.3) | LAMA-ICS | 4 (1.7) | |
| Total | 35 (14.7) | ICS-SABA-SAMA | 1 (0.4) | |
| LAMA/LAMA-ICS-T | 6 (2.5) | |||
| LABA-ICS-LAMA | 113 (47.5) | |||
| LABA-ICS-LAMA-T | 31 (13) | |||
| ICS-SABA-SAMA-T | 1 (0.4) | |||
| No drug use | 9 (3.8) | |||
| Total | 203 (85.3) | |||
| III | LABA-ICS | 30 (8.6) | LABA | 2 (0.6) |
| LAMA-ICS | 1 (0.3) | LAMA | 11 (3.2) | |
| LABA/LAMA-ICS-T | 11 (3.2) | T | 4 (1.2) | |
| LABA-ICS-LAMA | 156 (45.1) | ICS | 6 (1.7) | |
| LABA-ICS-LAMA-T | 94 (27.2) | LABA-LAMA | 5 (1.4) | |
| Total | 292 (84.4) | LABA-T | 1 (0.3) | |
| LAMA-T | 5 (1.4) | |||
| LABA-LAMA-T | 1 (0.3) | |||
| ICS-SABA-SAMA | 11 (3.2) | |||
| No drug use | 8 (2.3) | |||
| Total | 54 (15.6) | |||
| IV | LABA-ICS | 17 (14.3) | LABA | 1 (0.8) |
| LAMA-ICS | 1 (0.8) | LAMA | 1 (0.8) | |
| LABA/LAMA-ICS-T | 7 (5.9) | ICS | 5 (4.3) | |
| LABA-ICS-LAMA | 37 (31.1) | LABA-LAMA | 4 (3.4) | |
| LABA-ICS-LAMA-T | 37 (31.1) | LABA-T | 1 (0.8) | |
| Total | 99 (83.2) | LABA-LAMA-T | 1 (0.8) | |
| No drug use | 7 (5.9) | |||
| Total | 20 (16.8) | |||
| Total | 427 (59.4) | 292 (40.6) |
Abbreviations: ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SABA, short-acting β2-agonist; SAMA, short-acting muscarinic antagonist; T, theophylline.